About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Gt(ROSA)26Sortm1(rtTA*M2)Jae
targeted mutation 1, Rudolf Jaenisch
MGI:3702294
Summary 56 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Cd4tm1.1Tich/Cd4+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129 * 129S4/SvJae * C57BL/6 MGI:5470231
cn2
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Flt3tm1.1Dosm/Flt3tm1.1Dosm
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129 * C57BL/6 * C57BL/6NCrl MGI:5697542
cn3
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 MGI:4999988
cn4
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 MGI:5485201
cn5
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CAG-cat-lacZ)11Miya/0
Tg(Wnt1-cre)11Rth/0
involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2 MGI:5485200
cn6
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: C57BL/6 * C57BL/6NCrl MGI:5697539
cx7
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
chimera involves: 129S4/SvJae * C57BL/6 MGI:5000008
cx8
Cd4tm1.1Tich/Cd4+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129 * 129S4/SvJae * C57BL/6 MGI:5470229
cx9
Cd4tm1.1Tich/Cd4tm1.1Tich
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129 * 129S4/SvJae * C57BL/6 MGI:5470230
cx10
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4tm1Mak
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 MGI:5529094
cx11
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 MGI:5529093
cx12
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Tap1tm1Arp/Tap1tm1Arp
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 MGI:5478623
cx13
Col1a1tm6(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999991
cx14
Col1a1tm7(tetO-GFP/RNAi:rluc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5000004
cx15
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5000007
cx16
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5000010
cx17
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5000011
cx18
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5000012
cx19
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5000013
cx20
Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6 MGI:5007796
cx21
Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5051636
cx22
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1tm1(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5304756
cx23
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5304757
cx24
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1tm2(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5304758
cx25
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5304759
cx26
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/?
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5500065
cx27
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:4430610
cx28
Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4430611
cx29
Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4430612
cx30
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4822382
cx31
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999980
cx32
Col1a1tm2(tetO-GFP/RNAi:Trp53)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999981
cx33
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999985
cx34
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999987
cx35
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999989
cx36
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5316663
cx37
Col1a1tm1(tetO-Yap1*)Lrsn/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5430595
cx38
Col1a1tm2(tetO-Ctnnb1*)Hoch/Col1a1tm2(tetO-Ctnnb1*)Hoch
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6 MGI:5474007
cx39
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5478622
cx40
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5485198
cx41
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:3703249
cx42
Col1a1tm1(tetO-Cyp26b1)Mfra/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5585616
cx43
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5586502
cx44
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313419
cx45
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313421
cx46
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313423
cx47
Col1a1tm1(tetO-Deptor)Dmsa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5437856
cx48
Col1a1tm1(tetO-CTNNB1)Tcd/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5469373
cx49
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313420
cx50
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1 MGI:5294616
cx51
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1 MGI:5294614
cx52
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1 MGI:5294615
cx53
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5000009
cx54
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5000006
cx55
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5000014
cx56
Col1a1tm1(tetO-Stat1)Biat/Col1a1tm1(tetO-Stat1)Biat
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Stat1tm1Dlv/Stat1tm1Dlv
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 MGI:5698051


Genotype
MGI:5470231
cn1
Allelic
Composition
Cd4tm1.1Tich/Cd4+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129 * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd4tm1.1Tich mutation (0 available); any Cd4 mutation (43 available)
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (305 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• derepression of Cd4 occurs in all CD4- T cells (J:191711)
• T cell expression of CD4 increases rapidly after cre activation (J:191711)
• derepression of Cd4 occurs in all CD4- T cells (J:191711)
• T cell expression of CD4 increases rapidly after cre activation (J:191711)

hematopoietic system
• derepression of Cd4 occurs in all CD4- T cells (J:191711)
• T cell expression of CD4 increases rapidly after cre activation (J:191711)
• derepression of Cd4 occurs in all CD4- T cells (J:191711)
• T cell expression of CD4 increases rapidly after cre activation (J:191711)




Genotype
MGI:5697542
cn2
Allelic
Composition
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Flt3tm1.1Dosm/Flt3tm1.1Dosm
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
Genetic
Background
involves: 129 * C57BL/6 * C57BL/6NCrl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-IDH2*R140Q)Ppp mutation (0 available); any Col1a1 mutation (74 available)
Flt3tm1.1Dosm mutation (0 available); any Flt3 mutation (6 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• mice treated with doxycycline develop acute leukemias (J:210097)
• mice treated with doxycycline develop acute leukemias (J:210097)

mortality/aging
• reduced overall survival of doxycycline treated mice to 229 days vs 352 days for Flt3tm1.1Dosm controls (J:210097)
• reduced overall survival of doxycycline treated mice to 229 days vs 352 days for Flt3tm1.1Dosm controls (J:210097)




Genotype
MGI:4999988
cn3
Allelic
Composition
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(Luc)Kael mutation (2 available); any Gt(ROSA)26Sor mutation (305 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Krastm4Tyj mutation (4 available); any Kras mutation (30 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit reduced survival compared with control mice (J:171191)
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit reduced survival compared with control mice (J:171191)

tumorigenesis
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit increased tumor incidence (size and number) in the lungs with rare noninvasive lung adenomas compared with control mice (J:171191)
• however, mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit tumor regression after doxycycline removal (J:171191)
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit increased tumor incidence (size and number) in the lungs with rare noninvasive lung adenomas compared with control mice (J:171191)
• however, mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit tumor regression after doxycycline removal (J:171191)
• in mice treated with a cre-expressing adenovirus and treated with doxycycline (J:171191)
• in mice treated with a cre-expressing adenovirus and treated with doxycycline (J:171191)

respiratory system
• rapid shallow breathing in mice treated with a cre-expressing adenovirus and treated with doxycycline (J:171191)
• rapid shallow breathing in mice treated with a cre-expressing adenovirus and treated with doxycycline (J:171191)

growth/size/body
• in mice treated with a cre-expressing adenovirus and treated with doxycycline (J:171191)
• in mice treated with a cre-expressing adenovirus and treated with doxycycline (J:171191)




Genotype
MGI:5485201
cn4
Allelic
Composition
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
Genetic
Background
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EWSR1/ATF1)Yasu mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (1 available); any Gt(ROSA)26Sor mutation (305 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Tg(Mpz-cre)94Imeg mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• in of all doxycycline-treated mice arising from neural crest-lineage cells (J:194505)
• in of all doxycycline-treated mice arising from neural crest-lineage cells (J:194505)




Genotype
MGI:5485200
cn5
Allelic
Composition
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CAG-cat-lacZ)11Miya/0
Tg(Wnt1-cre)11Rth/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EWSR1/ATF1)Yasu mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Tg(CAG-cat-lacZ)11Miya mutation (0 available)
Tg(Wnt1-cre)11Rth mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• in of all doxycycline-treated mice arising from neural crest-lineage cells (J:194505)
• in of all doxycycline-treated mice arising from neural crest-lineage cells (J:194505)




Genotype
MGI:5697539
cn6
Allelic
Composition
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
Genetic
Background
involves: C57BL/6 * C57BL/6NCrl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-IDH2*R140Q)Ppp mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• modified IDH2 expression induced by doxycycline in chow starting around 3 weeks (J:210097)
• peripheral blood cell counts, number of hematopoietic stem cells, myeloid progenitors, mature B and T lymphocytes, and myeloid cells all normal when examined 8 weeks after induction (J:210097)
• modified IDH2 expression induced by doxycycline in chow starting around 3 weeks (J:210097)
• peripheral blood cell counts, number of hematopoietic stem cells, myeloid progenitors, mature B and T lymphocytes, and myeloid cells all normal when examined 8 weeks after induction (J:210097)
• KSL cells collected and plated out 8 weeks after induction display severely reduced erythroid colony formation but myeloid colony numbers are normal (J:210097)
• differentiation blockade is removed when doxycycline is removed from the culture medium (J:210097)
• KSL cells collected and plated out 8 weeks after induction display severely reduced erythroid colony formation but myeloid colony numbers are normal (J:210097)
• differentiation blockade is removed when doxycycline is removed from the culture medium (J:210097)
• by 7 months KSL cells are increased in bone marrow relative to controls (J:210097)
• long-term hematopoietic stem cells also tend to expand in number (J:210097)
• by 7 months KSL cells are increased in bone marrow relative to controls (J:210097)
• long-term hematopoietic stem cells also tend to expand in number (J:210097)
• significant extramedullary hematopoiesis (J:210097)
• significant extramedullary hematopoiesis (J:210097)
• about 1.3X larger than control spleens (J:210097)
• about 1.3X larger than control spleens (J:210097)

tumorigenesis
N
• no mice on doxycycline treatment for 1 year develop leukemia (J:210097)
• no mice on doxycycline treatment for 1 year develop leukemia (J:210097)
• infection of KSL cells with retrovirus containing HoxA9 and Meis1 and then injected into sub-lethally irradiated mice results in a pre-leukemic cell expansion (J:210097)
• infection of KSL cells with retrovirus containing HoxA9 and Meis1 and then injected into sub-lethally irradiated mice results in a pre-leukemic cell expansion (J:210097)

cellular
• KSL cells collected and plated out 8 weeks after induction display severely reduced erythroid colony formation but myeloid colony numbers are normal (J:210097)
• differentiation blockade is removed when doxycycline is removed from the culture medium (J:210097)
• KSL cells collected and plated out 8 weeks after induction display severely reduced erythroid colony formation but myeloid colony numbers are normal (J:210097)
• differentiation blockade is removed when doxycycline is removed from the culture medium (J:210097)
• by 7 months KSL cells are increased in bone marrow relative to controls (J:210097)
• long-term hematopoietic stem cells also tend to expand in number (J:210097)
• by 7 months KSL cells are increased in bone marrow relative to controls (J:210097)
• long-term hematopoietic stem cells also tend to expand in number (J:210097)

immune system
• about 1.3X larger than control spleens (J:210097)
• about 1.3X larger than control spleens (J:210097)




Genotype
MGI:5000008
cx7
Allelic
Composition
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
chimera involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• the founder mouse is sterile (J:171348)
• the founder mouse is sterile (J:171348)




Genotype
MGI:5470229
cx8
Allelic
Composition
Cd4tm1.1Tich/Cd4+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129 * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd4tm1.1Tich mutation (0 available); any Cd4 mutation (43 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• 15 days of doxycycline exposure leads to CD4 induction in all but the earliest CD4- thymocytes (not in DN1-3) (J:191711)
• only about 30% of peripheral CD8 cells begin expressing CD4 (J:191711)
• 15 days of doxycycline exposure leads to CD4 induction in all but the earliest CD4- thymocytes (not in DN1-3) (J:191711)
• only about 30% of peripheral CD8 cells begin expressing CD4 (J:191711)

hematopoietic system
• 15 days of doxycycline exposure leads to CD4 induction in all but the earliest CD4- thymocytes (not in DN1-3) (J:191711)
• only about 30% of peripheral CD8 cells begin expressing CD4 (J:191711)
• 15 days of doxycycline exposure leads to CD4 induction in all but the earliest CD4- thymocytes (not in DN1-3) (J:191711)
• only about 30% of peripheral CD8 cells begin expressing CD4 (J:191711)




Genotype
MGI:5470230
cx9
Allelic
Composition
Cd4tm1.1Tich/Cd4tm1.1Tich
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129 * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd4tm1.1Tich mutation (0 available); any Cd4 mutation (43 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• doxycycline treatment leads to detectable CD4+ CD8+ cells after 2 days (J:191711)
• levels of double positive cells reach 47% by 17 days after the start of treatment (J:191711)
• doxycycline treatment leads to detectable CD4+ CD8+ cells after 2 days (J:191711)
• levels of double positive cells reach 47% by 17 days after the start of treatment (J:191711)

hematopoietic system
• doxycycline treatment leads to detectable CD4+ CD8+ cells after 2 days (J:191711)
• levels of double positive cells reach 47% by 17 days after the start of treatment (J:191711)
• doxycycline treatment leads to detectable CD4+ CD8+ cells after 2 days (J:191711)
• levels of double positive cells reach 47% by 17 days after the start of treatment (J:191711)




Genotype
MGI:5529094
cx10
Allelic
Composition
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4tm1Mak
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Irf4)Sing mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Irf4tm1Mak mutation (1 available); any Irf4 mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)

immune system
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination but not as severe as in mice heterozygous for Irf4tm1Mak (J:203903)




Genotype
MGI:5529093
cx11
Allelic
Composition
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Irf4)Sing mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Irf4tm1Mak mutation (1 available); any Irf4 mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)

immune system
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)
• doxycycline-treated mice exhibit enhanced plasma cell generation at the expense of class switch recombination (J:203903)




Genotype
MGI:5478623
cx12
Allelic
Composition
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Tap1tm1Arp/Tap1tm1Arp
Genetic
Background
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Yod1*)Hpl mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Tap1tm1Arp mutation (3 available); any Tap1 mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• APCs from doxycycline-treated mice exhibit enhanced antigen cross-presentation compared with control cells (J:194608)
• APCs from doxycycline-treated mice exhibit enhanced antigen cross-presentation compared with control cells (J:194608)




Genotype
MGI:4999991
cx13
Allelic
Composition
Col1a1tm6(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm6(tetO-GFP/RNAi:Cdkn2a)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
phenotype not analyzed




Genotype
MGI:5000004
cx14
Allelic
Composition
Col1a1tm7(tetO-GFP/RNAi:rluc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm7(tetO-GFP/RNAi:rluc)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
phenotype not analyzed




Genotype
MGI:5000007
cx15
Allelic
Composition
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)

growth/size/body
• in doxycycline-treated mice (J:171348)
• in doxycycline-treated mice (J:171348)

cellular
• doxycycline-treated mice exhibit cell cycle arrest unlike control mice (J:171348)
• doxycycline-treated mice exhibit cell cycle arrest unlike control mice (J:171348)




Genotype
MGI:5000010
cx16
Allelic
Composition
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• when treated in utero with doxycycline, mice die shortly after birth (J:171348)
• when treated in utero with doxycycline, mice die shortly after birth (J:171348)

cellular
• doxycycline-treated mouse embryonic fibroblasts arrest in S phase with increased DNA content compared with untreated cells (J:171348)
• doxycycline-treated mouse embryonic fibroblasts arrest in S phase with increased DNA content compared with untreated cells (J:171348)
• doxycycline-treated mouse embryonic fibroblasts exhibit early cellular replicative senescence compared with untreated cells (J:171348)
• however, withdrawal of doxcycline restores proliferation (J:171348)
• doxycycline-treated mouse embryonic fibroblasts exhibit early cellular replicative senescence compared with untreated cells (J:171348)
• however, withdrawal of doxcycline restores proliferation (J:171348)

normal phenotype
• mice treated with doxycycline during adulthood exhibit no abnormal phenotype (J:171348)
• mice treated with doxycycline during adulthood exhibit no abnormal phenotype (J:171348)




Genotype
MGI:5000011
cx17
Allelic
Composition
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)
• all mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)

digestive/alimentary system
• doxycycline-treated adult mice exhibit atrophy of intestinal epithelium unlike control mice (J:171348)
• however, withdrawal of doxycycline reverses villus atrophy (J:171348)
• doxycycline-treated adult mice exhibit atrophy of intestinal epithelium unlike control mice (J:171348)
• however, withdrawal of doxycycline reverses villus atrophy (J:171348)
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)

hematopoietic system
• doxycycline-treated adult mice exhibit decreased erythroid precursors in the bone marrow unlike in control mice (J:171348)
• doxycycline-treated adult mice exhibit decreased erythroid precursors in the bone marrow unlike in control mice (J:171348)

growth/size/body
• in doxycycline-treated adult mice (J:171348)
• however, mice regain weight after withdrawal of doxycycline (J:171348)
• in doxycycline-treated adult mice (J:171348)
• however, mice regain weight after withdrawal of doxycycline (J:171348)

cellular
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)




Genotype
MGI:5000012
cx18
Allelic
Composition
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• when treated in utero with doxycycline, mice die shortly after birth (J:171348)
• when treated in utero with doxycycline, mice die shortly after birth (J:171348)

cellular
• doxycycline-treated mouse embryonic fibroblasts arrest in S phase with increased DNA content compared with untreated cells (J:171348)
• doxycycline-treated mouse embryonic fibroblasts arrest in S phase with increased DNA content compared with untreated cells (J:171348)
• doxycycline-treated mouse embryonic fibroblasts exhibit early cellular replicative senescence compared with untreated cells (J:171348)
• however, withdrawal of doxcycline restores proliferation (J:171348)
• doxycycline-treated mouse embryonic fibroblasts exhibit early cellular replicative senescence compared with untreated cells (J:171348)
• however, withdrawal of doxcycline restores proliferation (J:171348)

normal phenotype
• mice treated with doxycycline during adulthood exhibit no abnormal phenotype (J:171348)
• mice treated with doxycycline during adulthood exhibit no abnormal phenotype (J:171348)




Genotype
MGI:5000013
cx19
Allelic
Composition
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)
• all mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)

digestive/alimentary system
• doxycycline-treated adult mice exhibit atrophy of intestinal epithelium unlike control mice (J:171348)
• however, withdrawal of doxycycline reverses villus atrophy (J:171348)
• doxycycline-treated adult mice exhibit atrophy of intestinal epithelium unlike control mice (J:171348)
• however, withdrawal of doxycycline reverses villus atrophy (J:171348)
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)

hematopoietic system
• doxycycline-treated adult mice exhibit decreased erythroid precursors in the bone marrow unlike in control mice (J:171348)
• doxycycline-treated adult mice exhibit decreased erythroid precursors in the bone marrow unlike in control mice (J:171348)

growth/size/body
• in doxycycline-treated adult mice (J:171348)
• however, mice regain weight after withdrawal of doxycycline (J:171348)
• in doxycycline-treated adult mice (J:171348)
• however, mice regain weight after withdrawal of doxycycline (J:171348)

cellular
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice (J:171348)




Genotype
MGI:5007796
cx20
Allelic
Composition
Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
phenotype not analyzed




Genotype
MGI:5051636
cx21
Allelic
Composition
Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Tcfap2c)Hsc mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+ mice show increased proliferation and induced hepatic steatosis

mortality/aging
• within 6 to 7 days of doxycycline treatment (J:174049)
• within 6 to 7 days of doxycycline treatment (J:174049)

homeostasis/metabolism
• after doxycycline treatment, mice exhibit increased serum levels of aspartate transaminase, alanine transaminase, alkaline phosphatase, lipase, amylase, lactate dehydrogenase levels compared with control mice (J:174049)
• after doxycycline treatment, mice exhibit increased serum levels of aspartate transaminase, alanine transaminase, alkaline phosphatase, lipase, amylase, lactate dehydrogenase levels compared with control mice (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)

liver/biliary system
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria and increased mitophagy compared to in cells from control mice (J:174049)
• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria and increased mitophagy compared to in cells from control mice (J:174049)
• after doxycycline treatment, mice exhibit microvesicular steatosis unlike control mice (J:174049)
• after doxycycline treatment, mice exhibit microvesicular steatosis unlike control mice (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)

digestive/alimentary system
• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice (J:174049)
• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice (J:174049)
• after doxycycline treatment, the number of terminally differentiated intestinal cells (absorptive enterocytes, goblet cells, Paneth, cells and enteroendocrine cells) is reduced compared to in control mice (J:174049)
• after doxycycline treatment, the number of terminally differentiated intestinal cells (absorptive enterocytes, goblet cells, Paneth, cells and enteroendocrine cells) is reduced compared to in control mice (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment, the ratio of crypt length to villus length in the duodenum, jejunum, and ileum is increased compared to in control mice (J:174049)
• after doxycycline treatment, the ratio of crypt length to villus length in the duodenum, jejunum, and ileum is increased compared to in control mice (J:174049)

endocrine/exocrine glands
• after doxycycline treatment, mice exhibit pancreatic injury unlike control mice (J:174049)
• after doxycycline treatment, mice exhibit pancreatic injury unlike control mice (J:174049)

behavior/neurological
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)

growth/size/body
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)

immune system
N
• doxycycline-treated mice do not exhibit induction of inflammatory processes (J:174049)
• doxycycline-treated mice do not exhibit induction of inflammatory processes (J:174049)

cellular
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice (J:174049)
• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice (J:174049)
• after doxycycline treatment (J:174049)
• after doxycycline treatment (J:174049)




Genotype
MGI:5304756
cx22
Allelic
Composition
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1tm1(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-RNAi:Rps19)Karl mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice die within 2 months following doxycycline treatment (J:179085)
• most mice die within 2 months following doxycycline treatment (J:179085)

hematopoietic system
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment (J:179085)
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment (J:179085)
• by 10 days after doxycycline treatment (J:179085)
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment (J:179085)
• by 10 days after doxycycline treatment (J:179085)
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment (J:179085)
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment (J:179085)
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment (J:179085)

growth/size/body
• following doxycycline treatment (J:179085)
• following doxycycline treatment (J:179085)

digestive/alimentary system
• occasional dilated glands in the large intestine and colon (J:179085)
• occasional dilated glands in the large intestine and colon (J:179085)

immune system
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)

Mouse Models of Human Disease
OMIM ID Ref(s)
Diamond-Blackfan Anemia 1; DBA1 105650 J:179085




Genotype
MGI:5304757
cx23
Allelic
Composition
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-RNAi:Rps19)Karl mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment (J:179085)
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment (J:179085)

hematopoietic system
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment (J:179085)
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment (J:179085)
• by 10 days after doxycycline treatment (J:179085)
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment (J:179085)
• by 10 days after doxycycline treatment (J:179085)
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment (J:179085)
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment (J:179085)
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment (J:179085)

immune system
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)

growth/size/body
• following doxycycline treatment (J:179085)
• less pronounced than in homozygous mice (J:179085)
• following doxycycline treatment (J:179085)
• less pronounced than in homozygous mice (J:179085)

Mouse Models of Human Disease
OMIM ID Ref(s)
Diamond-Blackfan Anemia 1; DBA1 105650 J:179085




Genotype
MGI:5304758
cx24
Allelic
Composition
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1tm2(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-RNAi:Rps19)Karl mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice die within 2 months following doxycycline treatment (J:179085)
• most mice die within 2 months following doxycycline treatment (J:179085)

hematopoietic system
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)

growth/size/body
• following doxycycline treatment (J:179085)
• following doxycycline treatment (J:179085)

immune system
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)

Mouse Models of Human Disease
OMIM ID Ref(s)
Diamond-Blackfan Anemia 1; DBA1 105650 J:179085




Genotype
MGI:5304759
cx25
Allelic
Composition
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-RNAi:Rps19)Karl mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment (J:179085)
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment (J:179085)

hematopoietic system
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)
• two weeks after doxycycline treatment (J:179085)

growth/size/body
• following doxycycline treatment (J:179085)
• less pronounced than in homozygous mice (J:179085)
• following doxycycline treatment (J:179085)
• less pronounced than in homozygous mice (J:179085)

immune system
• two and seven weeks after doxycycline treatment (J:179085)
• two and seven weeks after doxycycline treatment (J:179085)

Mouse Models of Human Disease
OMIM ID Ref(s)
Diamond-Blackfan Anemia 1; DBA1 105650 J:179085




Genotype
MGI:5500065
cx26
Allelic
Composition
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/?
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• in doxycycline-treated neonates (J:196313)
• in doxycycline-treated neonates (J:196313)




Genotype
MGI:4430610
cx27
Allelic
Composition
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• mice exhibit no tumors or health problems up to 31 weeks (J:157298)
• mice exhibit no tumors or health problems up to 31 weeks (J:157298)




Genotype
MGI:4430611
cx28
Allelic
Composition
Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
phenotype not analyzed




Genotype
MGI:4430612
cx29
Allelic
Composition
Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
phenotype not analyzed




Genotype
MGI:4822382
cx30
Allelic
Composition
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm6(tetO-MSI2)Jae mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (J:163322)

hematopoietic system
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (J:163322)
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit a decrease in myeloid progenitor and myeloid erythrocroid progenitor cells compared with mice reconstituted with wild-type bone marrow (J:163322)
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit a decrease in myeloid progenitor and myeloid erythrocroid progenitor cells compared with mice reconstituted with wild-type bone marrow (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• doxycycline-treated mice exhibit an expansion of hematopoietic stem cells (HSCs) due to preferential expansion of short term HSC compared with wild-type mice (J:163322)
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit an increase in HSCs, hematopoietic progenitor cells, and long term HSCs compared with mice reconstituted with wild-type bone marrow (J:163322)
• doxycycline-treated mice exhibit an expansion of hematopoietic stem cells (HSCs) due to preferential expansion of short term HSC compared with wild-type mice (J:163322)
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit an increase in HSCs, hematopoietic progenitor cells, and long term HSCs compared with mice reconstituted with wild-type bone marrow (J:163322)
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow (J:163322)
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)

liver/biliary system
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)

tumorigenesis
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit an increase in the number of leukemic blasts and infiltration with immature myeloid cells compared with similarly treated wild-type mice reconstituted with wild-type bone marrow (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit an increase in the number of leukemic blasts and infiltration with immature myeloid cells compared with similarly treated wild-type mice reconstituted with wild-type bone marrow (J:163322)

immune system
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (J:163322)
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow (J:163322)
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow (J:163322)
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (J:163322)




Genotype
MGI:4999980
cx31
Allelic
Composition
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• doxycycline-treated mice are normal (J:171191)
• doxycycline-treated mice are normal (J:171191)




Genotype
MGI:4999981
cx32
Allelic
Composition
Col1a1tm2(tetO-GFP/RNAi:Trp53)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-GFP/RNAi:Trp53)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
phenotype not analyzed




Genotype
MGI:4999985
cx33
Allelic
Composition
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice with lymphoma exhibit median survival of 7.4 months (J:171191)
• doxycycline-treated mice with lymphoma exhibit median survival of 7.4 months (J:171191)

skeleton
• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice (J:171191)
• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice (J:171191)
• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice (J:171191)
• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice (J:171191)

integument
• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice (J:171191)
• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)
• however, reactivation after 4 weeks by doxycycline withdrawal prevents hair loss (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)
• however, reactivation after 4 weeks by doxycycline withdrawal prevents hair loss (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)

homeostasis/metabolism
• in mice treated with doxycycline at E8.5 (J:171191)
• however, mice transiently treated with doxycycline between E8.5 and E12.5 do not exhibit edema (J:171191)
• in mice treated with doxycycline at E8.5 (J:171191)
• however, mice transiently treated with doxycycline between E8.5 and E12.5 do not exhibit edema (J:171191)

limbs/digits/tail
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit extra digits (total 5 to 9) that are largely unsegmented and duplicated along their length compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit extra digits (total 5 to 9) that are largely unsegmented and duplicated along their length compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice (J:171191)
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice (J:171191)

growth/size/body
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)
• runting in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• runting in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• at E14.5 and E18.5 in mice treated with doxycycline at E8.5 (J:171191)
• at E14.5 and E18.5 in mice treated with doxycycline at E8.5 (J:171191)

tumorigenesis
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)

craniofacial
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)




Genotype
MGI:4999987
cx34
Allelic
Composition
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice with lymphoma exhibit median survival or 5.3 months (J:171191)
• doxycycline-treated mice with lymphoma exhibit median survival or 5.3 months (J:171191)

tumorigenesis
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)
• in mice treated with doxycycline from 4 to 6 weeks of age (J:171191)

integument
• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice (J:171191)
• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)
• however, reactivation after 4 weeks of doxycycline prevents hair loss (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)
• however, reactivation after 4 weeks of doxycycline prevents hair loss (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)
• in mice treated with doxycycline beyond 20 weeks (J:171191)

craniofacial
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)

growth/size/body
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout (J:171191)
• runting in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• runting in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)
• in mice treated with doxycycline 1 to 2 days prior to birth (J:171191)




Genotype
MGI:4999989
cx35
Allelic
Composition
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
phenotype not analyzed




Genotype
MGI:5316663
cx36
Allelic
Composition
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-YAP1*)Fcam mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice become ill and must be euthanized 4-6 days after doxycycline treatment (J:141457)
• mice become ill and must be euthanized 4-6 days after doxycycline treatment (J:141457)

digestive/alimentary system
• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice (J:141457)
• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline (J:141457)
• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal (J:141457)
• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice (J:141457)
• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline (J:141457)
• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal (J:141457)
• in doxycycline-treated mice (J:141457)
• in doxycycline-treated mice (J:141457)
• ductal metaplasia in doxycycline-treated mice (J:141457)
• ductal metaplasia in doxycycline-treated mice (J:141457)
• severe dysplasia in doxycycline-treated mice (J:141457)
• severe dysplasia in doxycycline-treated mice (J:141457)
• Paneth cells are absent 5 days after doxycycline treatment (J:141457)
• however, the absence of Paneth cells is reversed by doxycycline-withdrawal (J:141457)
• Paneth cells are absent 5 days after doxycycline treatment (J:141457)
• however, the absence of Paneth cells is reversed by doxycycline-withdrawal (J:141457)
• mature goblet cells are absent 5 days after doxycycline treatment (J:141457)
• however, the absence of mature goblet cells is reversed by doxycycline-withdrawal and administration of dipenzazepine increased goblet cell numbers (J:141457)
• mature goblet cells are absent 5 days after doxycycline treatment (J:141457)
• however, the absence of mature goblet cells is reversed by doxycycline-withdrawal and administration of dipenzazepine increased goblet cell numbers (J:141457)

endocrine/exocrine glands
• in doxycycline-treated mice (J:141457)
• in doxycycline-treated mice (J:141457)
• ductal metaplasia in doxycycline-treated mice (J:141457)
• ductal metaplasia in doxycycline-treated mice (J:141457)
• Paneth cells are absent 5 days after doxycycline treatment (J:141457)
• however, the absence of Paneth cells is reversed by doxycycline-withdrawal (J:141457)
• Paneth cells are absent 5 days after doxycycline treatment (J:141457)
• however, the absence of Paneth cells is reversed by doxycycline-withdrawal (J:141457)
• in doxycycline-treated mice (J:141457)
• in doxycycline-treated mice (J:141457)

cellular
• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice (J:141457)
• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline (J:141457)
• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal (J:141457)
• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice (J:141457)
• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline (J:141457)
• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal (J:141457)
• in the epidermis of doxycycline-treated mice (J:141457)
• in the epidermis of doxycycline-treated mice (J:141457)

homeostasis/metabolism
• absent in the small intestine 5 days after doxycycline treatment (J:141457)
• absent in the small intestine 5 days after doxycycline treatment (J:141457)

integument
• in doxycycline-treated mice (J:141457)
• in doxycycline-treated mice (J:141457)




Genotype
MGI:5430595
cx37
Allelic
Composition
Col1a1tm1(tetO-Yap1*)Lrsn/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Yap1*)Lrsn mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice die 10 days after treatment with doxycycline (J:185310)
• all mice die 10 days after treatment with doxycycline (J:185310)




Genotype
MGI:5474007
cx38
Allelic
Composition
Col1a1tm2(tetO-Ctnnb1*)Hoch/Col1a1tm2(tetO-Ctnnb1*)Hoch
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-Ctnnb1*)Hoch mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• after doxycycline treatment of adults (J:191050)
• number of intestinal stem cells is increased (J:191050)
• decreased cell division in colonic cells (J:191050)
• after doxycycline treatment of adults (J:191050)
• number of intestinal stem cells is increased (J:191050)
• decreased cell division in colonic cells (J:191050)
• crypt fission and budding is normalized after treatment with notch inhibitors (J:191050)
• crypt fission and budding is normalized after treatment with notch inhibitors (J:191050)
• crypt fission is often observed in the large intestine (J:191050)
• crypt fission is often observed in the large intestine (J:191050)
• crypt fission is often observed in the small intestine (J:191050)
• crypt fission is often observed in the small intestine (J:191050)
• suppressed cellular differentiation toward goblet cells (J:191050)
• suppressed cellular differentiation toward goblet cells (J:191050)

endocrine/exocrine glands
• crypt fission and budding is normalized after treatment with notch inhibitors (J:191050)
• crypt fission and budding is normalized after treatment with notch inhibitors (J:191050)
• crypt fission is often observed in the large intestine (J:191050)
• crypt fission is often observed in the large intestine (J:191050)
• crypt fission is often observed in the small intestine (J:191050)
• crypt fission is often observed in the small intestine (J:191050)




Genotype
MGI:5478622
cx39
Allelic
Composition
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Yod1*)Hpl mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• doxycycline-treated mice exhibit normal T cell distribution in lymphoid organs (J:194608)
• doxycycline-treated mice exhibit normal T cell distribution in lymphoid organs (J:194608)
• CD8+ T cells from doxycycline-treated mice exhibit enhanced response to immunization with viral infection and improved viral growth control compared with control cells (J:194608)
• CD8+ T cells from doxycycline-treated mice exhibit enhanced response to immunization with viral infection and improved viral growth control compared with control cells (J:194608)
• following exposure to ovalbumin, antigen presenting cells (APCs) from doxycycline-treated mice exhibit enhanced antigen cross-production with increased induction of proliferation and IL2 production in OT-I cells compared with control cells (J:194608)
• following infection with MHV-68 and irradiation, bone marrow derived dendritic cells from doxycycline-treated mice prime more effective CD8+ T cell response compared with control cells (J:194608)
• APCs from doxycycline-treated mice exhibit prolonged antigen retention compared with control cells (J:194608)
• cross-presentation in doxycycline-treated mice requires acidification and is insensitive to brefeldin compared to in control cells (J:194608)
• however, antigen presentation in doxycycline-treated mice is normal (J:194608)
• following exposure to ovalbumin, antigen presenting cells (APCs) from doxycycline-treated mice exhibit enhanced antigen cross-production with increased induction of proliferation and IL2 production in OT-I cells compared with control cells (J:194608)
• following infection with MHV-68 and irradiation, bone marrow derived dendritic cells from doxycycline-treated mice prime more effective CD8+ T cell response compared with control cells (J:194608)
• APCs from doxycycline-treated mice exhibit prolonged antigen retention compared with control cells (J:194608)
• cross-presentation in doxycycline-treated mice requires acidification and is insensitive to brefeldin compared to in control cells (J:194608)
• however, antigen presentation in doxycycline-treated mice is normal (J:194608)

hematopoietic system
• CD8+ T cells from doxycycline-treated mice exhibit enhanced response to immunization with viral infection and improved viral growth control compared with control cells (J:194608)
• CD8+ T cells from doxycycline-treated mice exhibit enhanced response to immunization with viral infection and improved viral growth control compared with control cells (J:194608)




Genotype
MGI:5485198
cx40
Allelic
Composition
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EWSR1/ATF1)Yasu mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• after 3 to 10 months of doxycycline-treated mice with median survival of 20 weeks (J:194505)
• after 3 to 10 months of doxycycline-treated mice with median survival of 20 weeks (J:194505)

tumorigenesis
• in doxycycline-treated mice following withdrawal of doxycycline (J:194505)
• in doxycycline-treated mice following withdrawal of doxycycline (J:194505)
• in the trunks, heads, limbs, and whisker pads of all doxycycline-treated mice after 3 months arising from neural crest-lineage cells (J:194505)
• in the trunks, heads, limbs, and whisker pads of all doxycycline-treated mice after 3 months arising from neural crest-lineage cells (J:194505)

cellular
• in doxycycline-treated mouse embryonic fibroblasts (J:194505)
• in doxycycline-treated mouse embryonic fibroblasts (J:194505)




Genotype
MGI:3703249
cx41
Allelic
Composition
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-Pou5f1)Jae mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice with doxycycline-induced ectopic Oct4 expression become morbid after 3-5 days of treatment and usually die after 5-10 days of treatment (J:98920)
• however, if doxycycline treatment is stopped after 5 days mice completely recover (J:98920)
• mice with doxycycline-induced ectopic Oct4 expression become morbid after 3-5 days of treatment and usually die after 5-10 days of treatment (J:98920)
• however, if doxycycline treatment is stopped after 5 days mice completely recover (J:98920)

digestive/alimentary system
• after doxycline treatment, dysplastic cells are found in the entire epithelium; cells have structural and cytological dysplasia which mimics adenocarcinoma (J:98920)
• after doxycline treatment, dysplastic cells are found in the entire epithelium; cells have structural and cytological dysplasia which mimics adenocarcinoma (J:98920)
• the proximal part of the small intestine is most severely affected by doxycycline treatment with abnormal cells often almost obstructing the lumen (J:98920)
• after 5 days of doxycycline treatment, proliferative zone expands; postmitotic, differentiated cells lining the villus are replaced (J:98920)
• upon cessation of treatment, cells migrate to final destinations and differentiate resulting in restoration of normal morphology (J:98920)
• the proximal part of the small intestine is most severely affected by doxycycline treatment with abnormal cells often almost obstructing the lumen (J:98920)
• after 5 days of doxycycline treatment, proliferative zone expands; postmitotic, differentiated cells lining the villus are replaced (J:98920)
• upon cessation of treatment, cells migrate to final destinations and differentiate resulting in restoration of normal morphology (J:98920)
• in doxycycline treated mice, cells in the forestomach show a marked atypia and increased mitotic activity (J:98920)
• in doxycycline treated mice, cells in the forestomach show a marked atypia and increased mitotic activity (J:98920)
• pyloric mucosa contains lesions resembling high grade-dysplasia in doxycycline treated mice (J:98920)
• pyloric mucosa contains lesions resembling high grade-dysplasia in doxycycline treated mice (J:98920)
• hyperplastic fundic glands are seen in doxycycline treated mice (J:98920)
• hyperplastic fundic glands are seen in doxycycline treated mice (J:98920)
• in doxycycline treated mice, forestomach epithelium is thickened and stomach shows lack of differentiation into granular and cornified cell layers compared to control mice (J:98920)
• the thickened epithelium consists of atypical cells with enlarged nuclei and prominent nucleoli (J:98920)
• in doxycycline treated mice, forestomach epithelium is thickened and stomach shows lack of differentiation into granular and cornified cell layers compared to control mice (J:98920)
• the thickened epithelium consists of atypical cells with enlarged nuclei and prominent nucleoli (J:98920)
• after doxycycline treatment, mice display severe dysplasia and increased proliferation (J:98920)
• after doxycycline treatment, mice display severe dysplasia and increased proliferation (J:98920)
• cells show atypia and increased mitotic activity throughout the squamous epithelial layer in doxycycline treated mice (J:98920)
• cells show atypia and increased mitotic activity throughout the squamous epithelial layer in doxycycline treated mice (J:98920)

homeostasis/metabolism
• after 3-5 days of doxycycline treatment, animals display severe dehydration (J:98920)
• after 3-5 days of doxycycline treatment, animals display severe dehydration (J:98920)

cellular
• abnormal cell proliferation is observed in several organs after 2 days of Oct4-induction (J:98920)
• however, complete reversion is seen with withdrawal of doxycycline treatment (J:98920)
• abnormal cell proliferation is observed in several organs after 2 days of Oct4-induction (J:98920)
• however, complete reversion is seen with withdrawal of doxycycline treatment (J:98920)

behavior/neurological
• animals become lethargic with doxycycline treatment within 3-5 days (J:98920)
• animals become lethargic with doxycycline treatment within 3-5 days (J:98920)

hematopoietic system
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice (J:98920)
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice (J:98920)
• in doxycycline treated mice (J:98920)
• in doxycycline treated mice (J:98920)

immune system
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice (J:98920)
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice (J:98920)
• in doxycycline treated mice (J:98920)
• in doxycycline treated mice (J:98920)

tumorigenesis
• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen (J:98920)
• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen (J:98920)

integument
• increased numbers of immature cells in the hair follicles of the skin are seen after 5-10 days of doxycycline (J:98920)
• increased numbers of immature cells in the hair follicles of the skin are seen after 5-10 days of doxycycline (J:98920)
• after 5-10 days of doxycycline treatment, mice show mild to moderate epidermal dysplasia with a decrease in differentiation in dysplastic cells (J:98920)
• after 5-10 days of doxycycline treatment, mice show mild to moderate epidermal dysplasia with a decrease in differentiation in dysplastic cells (J:98920)
• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen (J:98920)
• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen (J:98920)

endocrine/exocrine glands
• hyperplastic fundic glands are seen in doxycycline treated mice (J:98920)
• hyperplastic fundic glands are seen in doxycycline treated mice (J:98920)
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice (J:98920)
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice (J:98920)




Genotype
MGI:5585616
cx42
Allelic
Composition
Col1a1tm1(tetO-Cyp26b1)Mfra/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Cyp26b1)Mfra mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• mice treated with doxycycline at E8.5 exhibit smaller jugular lymph sac at E 14.5 compared with control mice (J:206581)
• mice treated with doxycycline at E8.5 exhibit smaller jugular lymph sac at E 14.5 compared with control mice (J:206581)




Genotype
MGI:5586502
cx43
Allelic
Composition
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Fosl1,-DsRed)Wag mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• periportal with immune infiltrate in doxycycline-treated mice (J:213764)
• periportal with immune infiltrate in doxycycline-treated mice (J:213764)

skeleton
• in doxycycline-treated mice at necropsy (J:213764)
• in doxycycline-treated mice at necropsy (J:213764)

growth/size/body
• in doxycycline-treated mice (J:213764)
• in doxycycline-treated mice (J:213764)

behavior/neurological
• in doxycycline-treated mice (J:213764)
• in doxycycline-treated mice (J:213764)

homeostasis/metabolism
• sometimes in doxycycline-treated mice at necropsy (J:213764)
• sometimes in doxycycline-treated mice at necropsy (J:213764)

hematopoietic system
• in doxycycline-treated mice at necropsy (J:213764)
• in doxycycline-treated mice at necropsy (J:213764)

immune system
• in doxycycline-treated mice at necropsy (J:213764)
• in doxycycline-treated mice at necropsy (J:213764)




Genotype
MGI:5313419
cx44
Allelic
Composition
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (8 available); any Apc mutation (53 available)
Col1a1tm9(tetO-Dnmt3b_i1)Jae mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• doxycycline-treated mice develop more macro- and microadenomas in the small intestinal and, to a lesser extent colon, compared with Apcmin heterozygotes (J:127808)
• doxycycline-treated mice exhibit increased size of microadenomas compared with Apcmin heterozygotes (J:127808)
• doxycycline-treated mice develop more macro- and microadenomas in the small intestinal and, to a lesser extent colon, compared with Apcmin heterozygotes (J:127808)
• doxycycline-treated mice exhibit increased size of microadenomas compared with Apcmin heterozygotes (J:127808)
• doxycycline-treated mice develop more macro- and microadenomas in the small intestinal and, to a lesser extent colon, compared with Apcmin heterozygotes (J:127808)
• doxycycline-treated mice develop more macro- and microadenomas in the small intestinal and, to a lesser extent colon, compared with Apcmin heterozygotes (J:127808)

cellular
• doxycycline-treated mice exhibit loss of imprinting and increased expression of Igf2 compared with control mice (J:127808)
• doxycycline-treated mice exhibit biallelic methylation of H19 differentially methylated region in tumors and normal colon epithelial cells compared with control mice (J:127808)
• doxycycline-treated mice exhibit hypermethylation of Sfrp2, Sfrp4 and Sfrp5 in tumors and normal colon epithelial cells unlike control mice (J:127808)
• however, mice exhibit normal methylation of of Snrpn differentially methylated region in tumors and normal colon epithelial cells, and global DNA methylation (J:127808)
• doxycycline-treated mice exhibit loss of imprinting and increased expression of Igf2 compared with control mice (J:127808)
• doxycycline-treated mice exhibit biallelic methylation of H19 differentially methylated region in tumors and normal colon epithelial cells compared with control mice (J:127808)
• doxycycline-treated mice exhibit hypermethylation of Sfrp2, Sfrp4 and Sfrp5 in tumors and normal colon epithelial cells unlike control mice (J:127808)
• however, mice exhibit normal methylation of of Snrpn differentially methylated region in tumors and normal colon epithelial cells, and global DNA methylation (J:127808)




Genotype
MGI:5313421
cx45
Allelic
Composition
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (8 available); any Apc mutation (53 available)
Col1a1tm11(tetO-Dnmt3b_i6)Jae mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
N
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes (J:127808)
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes (J:127808)




Genotype
MGI:5313423
cx46
Allelic
Composition
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (8 available); any Apc mutation (53 available)
Col1a1tm12(tetO-Dnmt3a_i1)Jae mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
N
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes (J:127808)
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes (J:127808)




Genotype
MGI:5437856
cx47
Allelic
Composition
Col1a1tm1(tetO-Deptor)Dmsa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Deptor)Dmsa mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• doxycycline treated mice gain more weight on a high fat diet; not caused by a difference in food intake or locomotion (J:187378)
• doxycycline treated mice gain more weight on a high fat diet; not caused by a difference in food intake or locomotion (J:187378)
• in doxycycline treated mice on a high fat diet (J:187378)
• in doxycycline treated mice on a high fat diet (J:187378)
• MEFs treated with doxycycline and differentiated in adipocytes show increased triglyceride accumulation (J:187378)
• MEFs treated with doxycycline and differentiated in adipocytes show increased triglyceride accumulation (J:187378)

adipose tissue
• in doxycycline treated mice on a high fat diet (J:187378)
• in doxycycline treated mice on a high fat diet (J:187378)

liver/biliary system
• in doxycycline treated mice on a high fat diet (J:187378)
• in doxycycline treated mice on a high fat diet (J:187378)
• in doxycycline treated mice on a high fat diet (J:187378)
• in doxycycline treated mice on a high fat diet (J:187378)

growth/size/body
• doxycycline treated mice gain more weight on a high fat diet; not caused by a difference in food intake or locomotion (J:187378)
• doxycycline treated mice gain more weight on a high fat diet; not caused by a difference in food intake or locomotion (J:187378)




Genotype
MGI:5469373
cx48
Allelic
Composition
Col1a1tm1(tetO-CTNNB1)Tcd/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-CTNNB1)Tcd mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• doxycycline-treated mice exhibit normal villus compartment (J:193365)
• doxycycline-treated mice exhibit normal villus compartment (J:193365)
• docycycline-treated mice exhibit apoptosis all along the enlarged crypt axis instead of being restricted to the bottom of the crypt as in control mice (J:193365)
• docycycline-treated mice exhibit apoptosis all along the enlarged crypt axis instead of being restricted to the bottom of the crypt as in control mice (J:193365)
• upon withdrawal of doxycycline (J:193365)
• upon withdrawal of doxycycline (J:193365)
• increased in the crypt compartment of doxycycline-treated mice (J:193365)
• increased in the crypt compartment of doxycycline-treated mice (J:193365)
• doxycycline-treated mice exhibit partially altered intestinal differentiation compared with control mice (J:193365)
• doxycycline-treated mice exhibit partially altered intestinal differentiation compared with control mice (J:193365)
• enlarged crypts in doxycycline-treated mice (J:193365)
• however, withdrawal of doxycycline leads to a rapid regression of the crypt compartment (J:193365)
• enlarged crypts in doxycycline-treated mice (J:193365)
• however, withdrawal of doxycycline leads to a rapid regression of the crypt compartment (J:193365)

growth/size/body
• in docycycline-treated mice (J:193365)
• in docycycline-treated mice (J:193365)

endocrine/exocrine glands
• enlarged crypts in doxycycline-treated mice (J:193365)
• however, withdrawal of doxycycline leads to a rapid regression of the crypt compartment (J:193365)
• enlarged crypts in doxycycline-treated mice (J:193365)
• however, withdrawal of doxycycline leads to a rapid regression of the crypt compartment (J:193365)

cellular
• docycycline-treated mice exhibit apoptosis all along the enlarged crypt axis instead of being restricted to the bottom of the crypt as in control mice (J:193365)
• docycycline-treated mice exhibit apoptosis all along the enlarged crypt axis instead of being restricted to the bottom of the crypt as in control mice (J:193365)
• upon withdrawal of doxycycline (J:193365)
• upon withdrawal of doxycycline (J:193365)
• increased in the crypt compartment of doxycycline-treated mice (J:193365)
• increased in the crypt compartment of doxycycline-treated mice (J:193365)




Genotype
MGI:5313420
cx49
Allelic
Composition
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (8 available); any Apc mutation (53 available)
Col1a1tm10(tetO-Dnmt3b_i3)Jae mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
N
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes (J:127808)
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes (J:127808)




Genotype
MGI:5294616
cx50
Allelic
Composition
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-LIN28B)Gqda mutation (1 available); any Col1a1 mutation (74 available)
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
N
• following doxycycline treatment responses in a glucose tolerance test are similar to controls (J:177113)
• following doxycycline treatment responses in a glucose tolerance test are similar to controls (J:177113)




Genotype
MGI:5294614
cx51
Allelic
Composition
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-LIN28B)Gqda mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• following doxycycline treatment mice gain less weight when fed a high fat diet compared to wild-type mice (J:177113)
• following doxycycline treatment mice gain less weight when fed a high fat diet compared to wild-type mice (J:177113)

homeostasis/metabolism
• following doxycycline treatment mice gain less weight when fed a high fat diet compared to wild-type mice (J:177113)
• following doxycycline treatment mice gain less weight when fed a high fat diet compared to wild-type mice (J:177113)
• following doxycycline treatment average fasting glucose is less than 50 mg/dL (J:177113)
• following doxycycline treatment average fasting glucose is less than 50 mg/dL (J:177113)
• following doxycycline treatment on a normal or high fat diet (J:177113)
• following doxycycline treatment on a normal or high fat diet (J:177113)
• following doxycycline treatment (J:177113)
• following doxycycline treatment (J:177113)




Genotype
MGI:5294615
cx52
Allelic
Composition
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda mutation (1 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• following doxycycline treatment (J:177113)
• following doxycycline treatment (J:177113)
• following doxycycline treatment (J:177113)
• following doxycycline treatment (J:177113)

homeostasis/metabolism
• in the fed state following doxycycline treatment (J:177113)
• in the fed state following doxycycline treatment (J:177113)
• during a glucose tolerance test in doxycycline treated mice (J:177113)
• however, no difference in insulin sensitivity is detected following doxycycline treatment (J:177113)
• during a glucose tolerance test in doxycycline treated mice (J:177113)
• however, no difference in insulin sensitivity is detected following doxycycline treatment (J:177113)
• following doxycycline treatment on a normal or high fat diet (J:177113)
• following doxycycline treatment on a normal or high fat diet (J:177113)




Genotype
MGI:5000009
cx53
Allelic
Composition
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Tg(CMV-rtTA)4Bjd mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)

growth/size/body
• in doxycycline-treated mice (J:171348)
• in doxycycline-treated mice (J:171348)




Genotype
MGI:5000006
cx54
Allelic
Composition
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Tg(CMV-rtTA)4Bjd mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• half of mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)
• half of mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)

growth/size/body
• in doxycycline-treated mice (J:171348)
• in doxycycline-treated mice (J:171348)

cellular
• doxycycline-treated mice exhibit cell cycle arrest in the liver, spleen, and intestine unlike control mice (J:171348)
• doxycycline-treated mice exhibit cell cycle arrest in the liver, spleen, and intestine unlike control mice (J:171348)




Genotype
MGI:5000014
cx55
Allelic
Composition
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Tg(CMV-rtTA)4Bjd mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely (J:171348)

growth/size/body
• in doxycycline-treated mice (J:171348)
• in doxycycline-treated mice (J:171348)




Genotype
MGI:5698051
cx56
Allelic
Composition
Col1a1tm1(tetO-Stat1)Biat/Col1a1tm1(tetO-Stat1)Biat
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Stat1tm1Dlv/Stat1tm1Dlv
Genetic
Background
involves: 129S/SvEv * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Stat1)Biat mutation (0 available); any Col1a1 mutation (74 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (12 available); any Gt(ROSA)26Sor mutation (305 available)
Stat1tm1Dlv mutation (7 available); any Stat1 mutation (23 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• Vesicular Stomatitis Virus or Encephalomyocarditis Virus infection results in death (J:212694)
• mice treated with doxycycline prior to viral infection survive at rates only slightly lower than wild-type controls (J:212694)
• Vesicular Stomatitis Virus or Encephalomyocarditis Virus infection results in death (J:212694)
• mice treated with doxycycline prior to viral infection survive at rates only slightly lower than wild-type controls (J:212694)

immune system
• Vesicular Stomatitis Virus or Encephalomyocarditis Virus infection results in death (J:212694)
• mice treated with doxycycline prior to viral infection survive at rates only slightly lower than wild-type controls (J:212694)
• Vesicular Stomatitis Virus or Encephalomyocarditis Virus infection results in death (J:212694)
• mice treated with doxycycline prior to viral infection survive at rates only slightly lower than wild-type controls (J:212694)





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory